iHub News
1月前
Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)May 19, 2026 9:31 AM
IH Market News Early Phase 2 data highlight promising efficacy and safety profile Relay Therapeutics Inc. (NASDAQ:RLAY) shares climbed 15% on Tuesday after the company released initial clinical results from its Phase 2 ReInspire study, showing that zovegalisib demonstrated encouraging safety and efficacy in patients with PIK3CA-driven vascular anomalies.The company reported a 60% volumetric response rate across dose groups at the 12-week mark, with all enrolled patients remaining on treatment throughout the study period.At the lowest evaluated dose of 100mg administered twice daily, 29% of patients achieved a volumetric response. Vascular anomalies are rare diseases involving abnormal growth and development of blood vessels, lymphatic vessels and surrounding tissue structures. Majority of evaluable patients showed lesion reduction As of the April 15, 2026 data cutoff, the trial had enrolled and randomized 32 patients across three dose cohorts within the adult and adolescent population.Among the 20 patients eligible for response evaluation, 60% achieved a volumetric response, defined as at least a 20% reduction in target lesion volume relative to baseline measurements. All responses were observed during the first MRI assessment.Interim findings from investigators and patients also showed clinical improvement rates of 89% and 79%, respectively, at week 12. Company expands study cohorts as development advances Relay Therapeutics said no patients discontinued treatment because of adverse events.Among the 22 patients receiving doses of 100mg and 300mg twice daily, dose reductions were reported in 23% of cases, while median dose intensity remained above 99%.The company has now opened expansion cohorts for adult and adolescent patients at doses of 400mg once daily and 300mg twice daily, while dose-finding work in pediatric patients continues.Relay is also advancing zovegalisib in oncology, including an ongoing Phase 3 study evaluating the drug in combination with fulvestrant for patients with PIK3CA-mutated, CDK4/6 pre-treated, HR+/HER2- advanced breast cancer.The clinical data were presented at the International Society for the Study of Vascular Anomalies World Congress 2026 held in Philadelphia.Relay Therapeutics stock price Original: Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY)
Whalatane
3月前
From Gemini
The scenario you described represents a significant competitive shift in the PI3K
a
??
mutant-selective inhibitor market, directly benefiting Relay Therapeutics ($RLAY) by potentially removing a primary clinical-stage competitor.
Strategic Impact of $COGT Discontinuing CGT6297
Reduced Competition: If Cogent Biosciences ($COGT) discontinues its lead PI3K
a
??
candidate, CGT6297, it would leave Relay's zovegalisib (RLY-2608) with a clearer path toward becoming the first-in-class mutant-selective therapy for PIK3CA-mutant breast cancer.
Pipeline Dominance: While Cogent indicates a shift toward "wild-type sparing" inhibitors, Relay's zovegalisib is already in a pivotal Phase 3 trial (ReDiscover-2). A reset by Cogent would likely put them several years behind Relay in clinical development.
Validation of Relay's Approach: Relay's focus on allosteric, mutant-selective inhibition is designed to avoid the hyperglycemia and toxicities associated with blocking wild-type PI3K
a
??
. A competitor switching strategies validates this exact molecular approach.
Current Good News for $RLAY
Stock Momentum: Relay's stock reached a new 52-week high of $12.17 today, April 2, 2026, marking a 12.95% daily gain.
Breakthrough Therapy Status: The FDA recently granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant, which is expected to expedite the drug's development and review timeline.
Strong Financial Position: With approximately $555 million in cash, Relay has a runway extending into 2029, fully funding its ongoing Phase 3 programs.
Positive Analyst Sentiment: Multiple analysts have recently upgraded the stock, with 12 "Buy" ratings and an average price target of $17.43.
US Market News
5月前
$207B Market Shift: The Race for Fast Track Approval in OncologyFebruary 5, 2026 9:35 AM
PR Newswire (Canada)
Issued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, Feb. 5, 2026 /CNW/ -- USANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued over 50 oncology approvals[1], but the real story is the aggressive pivot toward targeted therapies for high-unmet-need solid tumors. That momentum has accelerated in 2026 with a sudden flurry of expedited designations[2] for RAS inhibitors and rare malignancies. This regulatory velocity creates a clear validation framework, positioning Oncolytics Biotech Inc. (NASDAQ: ONCY), Relay Therapeutics (NASDAQ: RLAY), MAIA Biotechnology (NYSE-A: MAIA), Zai Lab (NASDAQ: ZLAB), and Arrivent BioPharma (NASDAQ: AVBP) directly at the convergence of urgent unmet medical need and commercial opportunity.
This is projected to be a $326.82 billion market opportunity by 2031[3], fueled by a robust expansion in antibody-drug conjugates and biomarker-driven regimens. But in biotech, time is the ultimate currency. Data confirms that Breakthrough Therapy Designation can slash late-stage development time by 30%[4]. For companies demonstrating clinical efficacy in difficult-to-treat populations, these expedited pathways are no longer just a bonus: they are the primary value drivers for scalable growth.Oncolytics Biotech Inc. (NASDAQ: ONCY) just received Fast Track Designation from the FDA for its cancer treatment pelareorep in second-line microsatellite-stable metastatic colorectal cancer patients with KRAS mutations. This regulatory status can enable more frequent FDA meetings and faster potential approval timelines, and it only gets granted when a treatment shows meaningful advantages over existing options.The designation is based on clinical data showing pelareorep combined with standard chemotherapy achieved a 33% response rate in KRAS-mutant microsatellite-stable (MSS) colorectal cancer patients, compared to roughly 10% with chemotherapy alone. More importantly, patients lived a median 27 months versus 11.2 months with standard treatment, and their cancer stayed stable for 16.6 months compared to 5.7 months. Response rate measures the percentage of patients whose tumors shrink significantly or disappear.This matters because KRAS-mutant MSS colorectal cancer represents one of the hardest-to-treat cancer populations, with limited options after first-line treatment fails and minimal benefit from immune therapies. The global market for second-line treatment in this patient group runs between $3 billion and $5 billion annually."Adding pelareorep to the standard-of-care in this underserved segment of colorectal cancer patients results in a doubling or tripling of critical clinical endpoints, including overall survival, progression-free survival, and objective response rate," said Jared Kelly, CEO of Oncolytics Biotech.The company plans to launch a controlled study comparing standard-of-care versus standard-of-care plus pelareorep, with the first clinical site activating in March and interim data expected by year-end 2026. This marks pelareorep's second Fast Track Designation in gastrointestinal cancers, following an earlier designation for pancreatic cancer.Oncolytics is building out its leadership team to handle these expanding programs. The company recently announced two critical hires: John McAdory as Executive Vice President of Strategy and Operations, who ran late-stage clinical trials at CG Oncology, and Yujun Wu as Vice President, Head of Biostatistics, who led statistics at Morphic Therapeutic through its sale to Eli Lilly. Kelly and Chief Business Officer Andrew Aromando both joined from Ambrx Biopharma, which sold to Johnson & Johnson for $2 billion in 2024.Pelareorep is also showing strong results in anal cancer, where third-line patients achieved a 29% response rate with responses lasting around 17 months in a setting with no FDA-approved treatments. In second-line anal cancer patients, the 30% response rate more than doubled the benchmark for available immunotherapy.CONTINUED… Read this and more news for Oncolytics Biotech at: https://usanewsgroup.com/2023/10/02/the-most-undervalued-oncolytics-company-on-the-nasdaq/ In other recent industry developments and happenings in the market include:Relay Therapeutics (NASDAQ: RLAY) has announced FDA Breakthrough Therapy designation for zovegalisib in combination with fulvestrant for PIK3CA-mutant HR+/HER2- locally advanced or metastatic breast cancer following progression on CDK4/6 inhibitor treatment. The designation was supported by clinical data from the ReDiscover trial with 600mg BID fasted and 400mg BID fed doses showing comparable exposures across all PIK3CA mutations."This Breakthrough Therapy designation underscores the FDA's recognition of the potential of zovegalisib in combination with fulvestrant to meaningfully improve outcomes for these patients, reinforcing the impact of the encouraging clinical evidence we have demonstrated to date," said Don Bergstrom, President of R&D at Relay Therapeutics.Initial Phase 1/2 data of zovegalisib plus fulvestrant at the 400mg BID fed Phase 3 dose in CDK4/6-experienced patients will be presented at the ESMO Targeted Anticancer Therapies Congress on March 16. Relay Therapeutics developed zovegalisib as the first known allosteric, pan-mutant, and isoform-selective PI3Ka inhibitor designed to overcome limitations of traditional orthosteric inhibitors.MAIA Biotechnology (NYSE-A: MAIA) has advanced its ateganosine program as the first and only telomere-targeting anticancer agent in clinical development, securing FDA Fast Track designation for the treatment of non-small cell lung cancer (NSCLC). The company initiated a pivotal Phase 3 trial in third-line NSCLC and expanded its Phase 2 trial with a $2.3 million NIH grant while establishing agreements with Roche and BeOne Medicines for checkpoint inhibitor combinations."MAIA's strong clinical execution in 2025 delivered exceptional efficacy data for ateganosine sequenced with a checkpoint inhibitor, including disease control, response rates, and survival data well above standard of care benchmarks," said Vlad Vitoc, CEO of MAIA Biotechnology. "Our statistical assessments of ateganosine imply a high probability of technical success in our concurrent Phase 3 and Phase 2 trials."The company targets potential commercial approval within 18 to 24 months, with 2026 milestones including interim Phase 3 efficacy data and Phase 2 trial conclusion. MAIA Biotechnology raised approximately $17.6 million in 2025 with board participation in nearly all transactions.Zai Lab (NASDAQ: ZLAB) announced that China's National Medical Products Administration has approved the supplemental New Drug Application for AUGTYRO™ (repotrectinib) for the treatment of adult patients with solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. The approval marks the second indication in China for the next-generation tyrosine kinase inhibitor, which demonstrated robust and durable efficacy and manageable safety in the pivotal Phase 1/2 TRIDENT-1 study."We are pleased with the NMPA's approval of AUGTYRO for patients with NTRK-positive solid tumors," said Rafael Amado, President, Head of Global Research and Development at Zai Lab. "This approval marks its second indication in China, addressing a critical treatment gap, as no prior therapy has been approved across both TKI-naïve and TKI-pretreated patients within this population."The approval represents the first in China to span both TRK TKI-naïve and TRK TKI-pretreated patients across solid tumors. Zai Lab has an exclusive license agreement with Bristol Myers Squibb to develop and commercialize AUGTYRO in Greater China, following their acquisition of Turning Point Therapeutics.Arrivent BioPharma (NASDAQ: AVBP) announced first patient dosing in the global pivotal Phase 3 ALPACCA trial evaluating firmonertinib for first-line treatment of EGFR PACC mutant non-small cell lung cancer. The oral, once-daily, brain-penetrant therapy demonstrated 16-month median progression-free survival and 68% confirmed objective response rate in the FURTHER trial, supporting selection of the 240 mg dose for pivotal development."Initiation of our pivotal Phase 3 ALPACCA trial marks an important milestone in our strategy to expand the global reach of firmonertinib," said Bing Yao, CEO of Arrivent BioPharma. "With a well-characterized safety profile and broad clinical systemic and central nervous system activity in patients, we believe firmonertinib is strongly positioned to bring meaningful innovation to NSCLC patients with PACC mutations."The ALPACCA study is designed to support potential global registration with endpoints for accelerated and full approval pathways. Arrivent BioPharma estimates the global ex-China annual incidence of NSCLC patients with EGFR PACC mutations to be approximately 42,000 patients and the US annual incidence to be approximately 6,200 patients.Source: https://usanewsgroup.com/2024/09/21/is-oncolytics-biotech-the-markets-most-undervalued-cancer-opportunity/ CONTACT:
USA NEWS GROUP
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles.While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:https://www.aacr.org/blog/2026/01/06/fda-approvals-in-oncology-october-december-2025/https://www.targetedonc.com/view/fda-oncology-update-january-2026-new-horizons-in-precision-medicinehttps://www.mordorintelligence.com/industry-reports/solid-tumor-therapeutics-markethttps://pmc.ncbi.nlm.nih.gov/articles/PMC12758617/Logo : https://mma.prnewswire.com/media/2838876/5764584/USA_News_Group_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/207b-market-shift-the-race-for-fast-track-approval-in-oncology-302680332.html
Original: $207B Market Shift: The Race for Fast Track Approval in Oncology
iHub News
5月前
Relay Therapeutics shares climb after Oppenheimer lifts ratingJanuary 26, 2026 3:01 PM
IH Market News
Shares of Relay Therapeutics Inc (NASDAQ:RLAY) jumped 5.8% in premarket trading on Monday after Oppenheimer upgraded the biotechnology company to Outperform from Perform and set a new price target of $14.00.Analyst Matt Biegler pointed to potential near-term catalysts for Relay’s mutant-selective inhibitor zovegalisib, particularly ahead of the upcoming VIKTORIA-1 clinical trial results for rival drug gedatolisib. Biegler expects the VIKTORIA-1 data to disappoint, arguing that the trial “will underperform expectations, and may even fail,” which could improve the competitive outlook for Relay’s program.“We think anything less than ’teenage’ mPFS for the gedatolisib triplet would create a beatable bar for Relay, who is developing a competing triplet with zovegalisib,” Biegler wrote in his note. He also likened gedatolisib to everolimus, suggesting it could encounter comparable limitations in PI3K inhibition.Relay’s stock has faced pressure since October, when early data from the wild-type cohort of the VIKTORIA-1 study exceeded investor expectations. However, Oppenheimer believes achieving similar results in patients with PI3K-mutant disease will be more challenging for gedatolisib, especially in light of recent clinical outcomes from competing therapies.The newly issued $14.00 price target implies substantial upside from current levels, underscoring Oppenheimer’s confidence in Relay Therapeutics’ positioning within the targeted oncology space.Relay Therapeutics stock price
Original: Relay Therapeutics shares climb after Oppenheimer lifts rating
georgie18
1年前
RLAY...$3.45...HOD...Nice Block Buying...
georgie18
Member Level
Re: georgie18 post# 21
Wednesday, April 30, 2025 3:02:49 PM
Post#
22
of 22
RLAY...$3.37...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 680203
Thursday, April 24, 2025 3:58:22 PM
Post#
680376
of 680836
RLAY...$3.20...🥳
georgie18
Member Level
Re: georgie18 post# 19
Wednesday, April 23, 2025 10:11:44 AM
Post#
20
of 20
RLAY...$3.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 679585
Tuesday, April 15, 2025 9:39:20 AM
Post#
679627
of 680201
RLAY...$2.67...🥳...Off the $2 range bottom...
georgie18
Member Level
Re: georgie18 post# 17
Monday, April 14, 2025 2:52:07 PM
Post#
18
of 18
RLAY...$2.51...HOD...🥳...In at $2.60 range average...
georgie18
Member Level
Re: georgie18 post# 677635
Friday, April 11, 2025 1:07:01 PM
Post#
679413
of 679584
RLAY...Added the $2 range dip...🥳...Averaged down to $2.60 range...
georgie18
Member Level
Re: georgie18 post# 15
Friday, March 21, 2025 1:28:34 PM
Post#
16
of 16
RLAY...$3.09...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 677132
Tuesday, March 18, 2025 7:49:29 PM
Post#
677237
of 677634
RLAY...$3.36...🥳...
georgie18
Member Level
Re: georgie18 post# 12
Tuesday, March 18, 2025 9:39:06 AM
Post#
14
of 14
RLAY...$3.30...Added here...🥳
georgie18
Member Level
Re: None
Monday, March 17, 2025 7:46:15 AM
Post#
676993
of 677131
RLAY...$3.66...🥳... https://schrts.co/TCfQFhkJ ...Bullish Psar Flip...Strong Money Flowand Accumulation... Bidding in the low $3 range as well...
georgie18
1年前
RLAY...$3.37...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 680203
Thursday, April 24, 2025 3:58:22 PM
Post#
680376
of 680836
RLAY...$3.20...🥳
georgie18
Member Level
Re: georgie18 post# 19
Wednesday, April 23, 2025 10:11:44 AM
Post#
20
of 20
RLAY...$3.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 679585
Tuesday, April 15, 2025 9:39:20 AM
Post#
679627
of 680201
RLAY...$2.67...🥳...Off the $2 range bottom...
georgie18
Member Level
Re: georgie18 post# 17
Monday, April 14, 2025 2:52:07 PM
Post#
18
of 18
RLAY...$2.51...HOD...🥳...In at $2.60 range average...
georgie18
Member Level
Re: georgie18 post# 677635
Friday, April 11, 2025 1:07:01 PM
Post#
679413
of 679584
RLAY...Added the $2 range dip...🥳...Averaged down to $2.60 range...
georgie18
Member Level
Re: georgie18 post# 15
Friday, March 21, 2025 1:28:34 PM
Post#
16
of 16
RLAY...$3.09...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 677132
Tuesday, March 18, 2025 7:49:29 PM
Post#
677237
of 677634
RLAY...$3.36...🥳...
georgie18
Member Level
Re: georgie18 post# 12
Tuesday, March 18, 2025 9:39:06 AM
Post#
14
of 14
RLAY...$3.30...Added here...🥳
georgie18
Member Level
Re: None
Monday, March 17, 2025 7:46:15 AM
Post#
676993
of 677131
RLAY...$3.66...🥳... https://schrts.co/TCfQFhkJ ...Bullish Psar Flip...Strong Money Flowand Accumulation... Bidding in the low $3 range as well...
georgie18
1年前
RLAY...$3.20...🥳
georgie18
Member Level
Re: georgie18 post# 19
Wednesday, April 23, 2025 10:11:44 AM
Post#
20
of 20
RLAY...$3.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 679585
Tuesday, April 15, 2025 9:39:20 AM
Post#
679627
of 680201
RLAY...$2.67...🥳...Off the $2 range bottom...
georgie18
Member Level
Re: georgie18 post# 17
Monday, April 14, 2025 2:52:07 PM
Post#
18
of 18
RLAY...$2.51...HOD...🥳...In at $2.60 range average...
georgie18
Member Level
Re: georgie18 post# 677635
Friday, April 11, 2025 1:07:01 PM
Post#
679413
of 679584
RLAY...Added the $2 range dip...🥳...Averaged down to $2.60 range...
georgie18
Member Level
Re: georgie18 post# 15
Friday, March 21, 2025 1:28:34 PM
Post#
16
of 16
RLAY...$3.09...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 677132
Tuesday, March 18, 2025 7:49:29 PM
Post#
677237
of 677634
RLAY...$3.36...🥳...
georgie18
Member Level
Re: georgie18 post# 12
Tuesday, March 18, 2025 9:39:06 AM
Post#
14
of 14
RLAY...$3.30...Added here...🥳
georgie18
Member Level
Re: None
Monday, March 17, 2025 7:46:15 AM
Post#
676993
of 677131
RLAY...$3.66...🥳... https://schrts.co/TCfQFhkJ ...Bullish Psar Flip...Strong Money Flowand Accumulation... Bidding in the low $3 range as well...
georgie18
1年前
RLAY...$3.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 679585
Tuesday, April 15, 2025 9:39:20 AM
Post#
679627
of 680201
RLAY...$2.67...🥳...Off the $2 range bottom...
georgie18
Member Level
Re: georgie18 post# 17
Monday, April 14, 2025 2:52:07 PM
Post#
18
of 18
RLAY...$2.51...HOD...🥳...In at $2.60 range average...
georgie18
Member Level
Re: georgie18 post# 677635
Friday, April 11, 2025 1:07:01 PM
Post#
679413
of 679584
RLAY...Added the $2 range dip...🥳...Averaged down to $2.60 range...
georgie18
Member Level
Re: georgie18 post# 15
Friday, March 21, 2025 1:28:34 PM
Post#
16
of 16
RLAY...$3.09...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 677132
Tuesday, March 18, 2025 7:49:29 PM
Post#
677237
of 677634
RLAY...$3.36...🥳...
georgie18
Member Level
Re: georgie18 post# 12
Tuesday, March 18, 2025 9:39:06 AM
Post#
14
of 14
RLAY...$3.30...Added here...🥳
georgie18
Member Level
Re: None
Monday, March 17, 2025 7:46:15 AM
Post#
676993
of 677131
RLAY...$3.66...🥳... https://schrts.co/TCfQFhkJ ...Bullish Psar Flip...Strong Money Flowand Accumulation... Bidding in the low $3 range as well...
georgie18
1年前
RLAY...$2.67...🥳...Off the $2 range bottom...
georgie18
Member Level
Re: georgie18 post# 17
Monday, April 14, 2025 2:52:07 PM
Post#
18
of 18
RLAY...$2.51...HOD...🥳...In at $2.60 range average...
georgie18
Member Level
Re: georgie18 post# 677635
Friday, April 11, 2025 1:07:01 PM
Post#
679413
of 679584
RLAY...Added the $2 range dip...🥳...Averaged down to $2.60 range...
georgie18
Member Level
Re: georgie18 post# 15
Friday, March 21, 2025 1:28:34 PM
Post#
16
of 16
RLAY...$3.09...Added here...🥳
georgie18
Member Level
Re: georgie18 post# 677132
Tuesday, March 18, 2025 7:49:29 PM
Post#
677237
of 677634
RLAY...$3.36...🥳...
georgie18
Member Level
Re: georgie18 post# 12
Tuesday, March 18, 2025 9:39:06 AM
Post#
14
of 14
RLAY...$3.30...Added here...🥳
georgie18
Member Level
Re: None
Monday, March 17, 2025 7:46:15 AM
Post#
676993
of 677131
RLAY...$3.66...🥳... https://schrts.co/TCfQFhkJ ...Bullish Psar Flip...Strong Money Flowand Accumulation... Bidding in the low $3 range as well...
georgie18
1年前
RLAY...$4.89...HOD...🥳...Hit $5.99 on Friday...
georgie18
Member Level
Re: georgie18 post# 388314
Friday, January 10, 2025 1:35:14 PM
Post#
388363
of 388440
RLAY...$5.40...🥳...on the Breakout...off my $4.61 Alert...
georgie18
Member Level
Re: georgie18 post# 667618
Wednesday, January 08, 2025 5:37:01 PM
Post#
670914
of 671062
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz
georgie18
Member Level
Re: georgie18 post# 386855
Thursday, December 12, 2024 9:51:02 AM
Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...
georgie18
Member Level
Re: georgie18 post# 667203
Wednesday, December 11, 2024 2:48:21 PM
Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html
georgie18
Member Level
Re: RIGATONI post# 386680
Saturday, December 07, 2024 12:12:54 PM
Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
georgie18
1年前
RLAY...$5.40...🥳...on the Breakout...off my $4.61 Alert...
georgie18
Member Level
Re: georgie18 post# 667618
Wednesday, January 08, 2025 5:37:01 PM
Post#
670914
of 671062
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz
georgie18
Member Level
Re: georgie18 post# 386855
Thursday, December 12, 2024 9:51:02 AM
Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...
georgie18
Member Level
Re: georgie18 post# 667203
Wednesday, December 11, 2024 2:48:21 PM
Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html
georgie18
Member Level
Re: RIGATONI post# 386680
Saturday, December 07, 2024 12:12:54 PM
Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
georgie18
1年前
RLAY...$4.93...🥳...Off my $4.61 Alert...Bullish Psar flip..."W" Pattern in play here...Break/Hold $5.21 and we see $6.50/47 range...https://schrts.co/nAzyZemz
georgie18
Member Level
Re: georgie18 post# 386855
Thursday, December 12, 2024 9:51:02 AM
Post#
386875
of 388314
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...
georgie18
Member Level
Re: georgie18 post# 667203
Wednesday, December 11, 2024 2:48:21 PM
Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html
georgie18
Member Level
Re: RIGATONI post# 386680
Saturday, December 07, 2024 12:12:54 PM
Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
georgie18
2年前
RLAY...$5.13...🥳Having solid News lately on this Bottom Chart...
georgie18
Member Level
Re: georgie18 post# 667203
Wednesday, December 11, 2024 2:48:21 PM
Post#
667564
of 667617
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html
georgie18
Member Level
Re: RIGATONI post# 386680
Saturday, December 07, 2024 12:12:54 PM
Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
georgie18
2年前
RLAY...$4.90s clearing here...🥳...https://www.globenewswire.com/news-release/2024/12/11/2995182/0/en/Relay-Therapeutics-Announces-Updated-Interim-Data-for-RLY-2608-Fulvestrant-Demonstrating-Continued-Maturation-of-Clinically-Meaningful-Progression-Free-Survival.html
georgie18
Member Level
Re: RIGATONI post# 386680
Saturday, December 07, 2024 12:12:54 PM
Post#
386697
of 386855
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
georgie18
2年前
RLAY...$4.61...🥳... https://schrts.co/dAgygcri ...Bullish Matching Low Reversal Pattern to the Upside...Confirmation Candle coming off the Oversold Bottom...
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Lirafugratinib is a potential best-in-class FGFR2 inhibitor that has shown differentiated efficacy in FGFR2-driven cholangiocarcinoma and demonstrated durable responses across multiple other types of FGFR2-altered solid tumors
Relay Therapeutics has potential to receive up to $500 million in upfront, regulatory and commercial milestone payments, including $75 million in upfront and regulatory milestones, plus up to double digit royalties on global sales
CAMBRIDGE, Mass. and FORT LEE, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, and Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated to elevating treatment outcomes for patients who have limited or inadequate therapeutic options, today announced an exclusive global licensing agreement for lirafugratinib (RLY-4008). Lirafugratinib is a selective oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2) that is being developed for patients with FGFR2-driven cholangiocarcinoma (CCA) and other FGFR2-altered solid tumors. The announcement of the partnership follows Relay’s recent positive FDA interaction and previously reported differentiated data in cholangiocarcinoma and data across other solid tumors.
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Monksdream
1年前
glenn1919
2年前
メールアドレスで登録
